Patient support programs are under more financial scrutiny than at any point in the past decade. Budgets are tightening, programs are being cut, and the leaders who run these programs are being asked to justify their existence in terms the C-suite understands. The problem is that the most important things PSPs do, keeping patients on therapy, reducing abandonment, and closing the gap between prescription and first fill, are difficult to express in the language of quarterly earnings calls.
At Hub West 2026, leaders from Propensity4/Inizio Engage, GSK, Nuvera Life Science Consulting, and Mirum Pharmaceuticals tackled this challenge head-on: how do you tell the story of program value when the audience is conditioned to think in revenue terms?
The C-Suite Conversation Problem
Most patient services leaders know their programs work. They see the patients who would have abandoned treatment but stayed because a case manager navigated a prior authorization. They see the prescription that would have gone unfilled but was rescued because a copay program made it affordable. They see the adherence that would have collapsed but held because proactive outreach caught the problem early.
The challenge is translating these individual patient stories into a narrative that resonates with finance, commercial leadership, and the CEO. Saying “we helped 4,200 patients stay on therapy” is meaningful in a patient services meeting. In a board room, the response is: what did that cost us, and what did it earn?
The panelists emphasized that this is not a data problem. Most PSP teams have plenty of data. It is a storytelling problem. The data exists, but it is not being assembled into a narrative that connects patient outcomes to business outcomes in a way that decision-makers find compelling.
Beyond Outdated Metrics
One of the most valuable insights from the session was the critique of legacy KPIs that many PSP teams still rely on. Metrics like average speed of answer, call volume, and application completion rates were designed for a contact center model. They measure operational throughput, not patient impact.
The panelists advocated for a new generation of KPIs that align with what actually matters: speed to therapy (the time between prescription and first fill or first administration), first-fill abandonment rate and how PSP intervention affects it, patient retention at key milestones (30 days, 90 days, 6 months, 12 months), re-engagement rates for patients who lapsed and were brought back to therapy, and patient-reported experience and satisfaction with the support they received.
These metrics tell a story that the C-suite can follow: patients are starting therapy faster, staying on therapy longer, and coming back to therapy when they lapse. And each of those outcomes has a revenue implication that finance can model.
Advocating for PSPs Under Budget Pressure
The reality in 2026 is that many patient services organizations are being asked to do more with less, or to justify why their budgets should not be reduced. The panelists offered several strategies for this environment.
First, connect PSP outcomes to commercial outcomes explicitly. When a PSP intervention prevents first-fill abandonment, that is a prescription that was filled. When an adherence program keeps a patient on therapy for an additional three months, that is three months of revenue that would have been lost. Building these connections into regular reporting, rather than waiting for a budget defense conversation, keeps the value proposition visible.
Second, benchmark against industry data. When your PSP can demonstrate that its first-fill abandonment rate is below industry average, or that its speed-to-therapy is faster than comparable programs, that is a competitive advantage that the business understands.
Third, bring patient stories to life alongside the data. A single patient story that illustrates what the program does, a real person whose treatment journey was transformed by the support they received, is more memorable than a table of metrics. The combination of data and narrative is more powerful than either alone.
Where Physician-Led Education Drives Measurable Impact
At Hoot, we have seen the data challenge from the other side. When a physician records a short educational video and that video is delivered to a patient via SMS at the moment they are deciding whether to fill their prescription, the impact is measurable and attributable. We can track delivery, engagement, and the downstream treatment decision.
This creates a clean data story for patient services leaders: patients who received physician-led education at key moments in their journey had higher initiation rates, better adherence, and lower abandonment. That is the kind of data that translates directly into the C-suite narrative, patients supported, revenue retained, and outcomes improved, all attributable to a specific intervention.
For PSP leaders under budget pressure, adding physician-led patient education to the support ecosystem is not an additional cost line. It is an investment that generates measurable, reportable patient outcomes that strengthen the case for the entire program.